CN101294956B - 人视黄醇结合蛋白-4在代谢异常的检测中的应用 - Google Patents
人视黄醇结合蛋白-4在代谢异常的检测中的应用 Download PDFInfo
- Publication number
- CN101294956B CN101294956B CN2007100401806A CN200710040180A CN101294956B CN 101294956 B CN101294956 B CN 101294956B CN 2007100401806 A CN2007100401806 A CN 2007100401806A CN 200710040180 A CN200710040180 A CN 200710040180A CN 101294956 B CN101294956 B CN 101294956B
- Authority
- CN
- China
- Prior art keywords
- rbp4
- antibody
- monoclonal antibody
- albumen
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001514 detection method Methods 0.000 title claims description 46
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 title description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 title description 2
- 230000004060 metabolic process Effects 0.000 title 1
- 229960003471 retinol Drugs 0.000 title 1
- 235000020944 retinol Nutrition 0.000 title 1
- 239000011607 retinol Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 74
- 201000010099 disease Diseases 0.000 claims abstract description 42
- 230000023852 carbohydrate metabolic process Effects 0.000 claims abstract description 35
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 35
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims abstract description 33
- 101000665882 Homo sapiens Retinol-binding protein 4 Proteins 0.000 claims abstract description 30
- 102000046481 human RBP4 Human genes 0.000 claims description 29
- 210000004408 hybridoma Anatomy 0.000 claims description 24
- 102100038246 Retinol-binding protein 4 Human genes 0.000 abstract description 153
- 108010074051 C-Reactive Protein Proteins 0.000 abstract description 20
- 102100032752 C-reactive protein Human genes 0.000 abstract description 20
- 108010076365 Adiponectin Proteins 0.000 abstract description 18
- 102000011690 Adiponectin Human genes 0.000 abstract description 18
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 11
- 208000035197 Disorder of carbohydrate metabolism Diseases 0.000 abstract 3
- 208000020450 carbohydrate metabolism disease Diseases 0.000 abstract 3
- 208000035762 Disorder of lipid metabolism Diseases 0.000 abstract 2
- 102000029752 retinol binding Human genes 0.000 abstract 1
- 108091000053 retinol binding Proteins 0.000 abstract 1
- 101710137011 Retinol-binding protein 4 Proteins 0.000 description 152
- 239000000523 sample Substances 0.000 description 80
- 210000002966 serum Anatomy 0.000 description 41
- 208000035475 disorder Diseases 0.000 description 31
- 238000012360 testing method Methods 0.000 description 29
- 238000000034 method Methods 0.000 description 27
- 208000001145 Metabolic Syndrome Diseases 0.000 description 20
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 238000010790 dilution Methods 0.000 description 20
- 239000012895 dilution Substances 0.000 description 20
- 206010022489 Insulin Resistance Diseases 0.000 description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000007790 solid phase Substances 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 12
- 235000015097 nutrients Nutrition 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 230000000630 rising effect Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000013024 dilution buffer Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000003908 quality control method Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 241000276498 Pollachius virens Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- -1 urase Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007156 Resistin Human genes 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 102000057799 human ADIPOQ Human genes 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 101150024910 rbp4 gene Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Abstract
Description
管号 | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
浓度ng/ml | 500 | 250 | 100 | 50 | 25 | 10 | 1 |
样品 | 平均值(μg/ml) | SD(μg/ml) | CV(%) |
1 | 21.58 | 0.54 | 2.5 |
2 | 31.40 | 0.44 | 1.4 |
3 | 46.17 | 1.54 | 3.3 |
样品 | 平均值(μg/ml) | SD(μg/ml) | CV(%) |
1 | 21.16 | 0.47 | 2.2 |
2 | 32.04 | 1.59 | 5.0 |
3 | 36.76 | 1.90 | 5.2 |
4 | 46.15 | 1.61 | 3.5 |
5 | 52.32 | 1.58 | 3.0 |
被分析物 | 最大浓度(μg/ml) | 交叉反应(%) |
人RBP4人抵抗素(Resistin)人脂联素(Adiponect in)人瘦素(Lept in)人胰岛素人TNF-α人MCP-1大鼠血清小鼠血清 | 0.10.020.061110.07 | 100N.R.N.R.N.R.N.R.N.R.N.R.N.R.N.R. |
样品 | 血清(μg/ml) | 血浆(EDTA)(μg/ml) |
1 | 27.84 | 27.80 |
2 | 33.19 | 29.34 |
3 | 49.80 | 48.04 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100401806A CN101294956B (zh) | 2007-04-28 | 2007-04-28 | 人视黄醇结合蛋白-4在代谢异常的检测中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100401806A CN101294956B (zh) | 2007-04-28 | 2007-04-28 | 人视黄醇结合蛋白-4在代谢异常的检测中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101294956A CN101294956A (zh) | 2008-10-29 |
CN101294956B true CN101294956B (zh) | 2012-08-15 |
Family
ID=40065371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100401806A Expired - Fee Related CN101294956B (zh) | 2007-04-28 | 2007-04-28 | 人视黄醇结合蛋白-4在代谢异常的检测中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101294956B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101833009A (zh) * | 2010-04-29 | 2010-09-15 | 浙江康特生物科技有限公司 | 一种双抗体复合的视黄醇结合蛋白检测试剂盒 |
CN103760334B (zh) * | 2014-01-28 | 2015-09-30 | 成都创宜生物科技有限公司 | 以Acrp30作为标志物制备检测工具的应用及检测工具 |
EP3638238A4 (en) | 2017-06-15 | 2021-03-10 | Belite Bio, Inc | METHODS FOR TREATING METABOLIC DISEASES WITH FUSION BICYCLIC PYRAZOLES |
CA3146130A1 (en) | 2019-07-08 | 2021-01-14 | Belite Bio, Llc | Formulations of rbp4 inhibitors and methods of use |
-
2007
- 2007-04-28 CN CN2007100401806A patent/CN101294956B/zh not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
CHO等.Plasma Retinol-Binding Protein-4 Concentrations Are Elevated in Human Subjects With Impaired Glucose Tolerance and Type 2 Diabetes.《DIABETES CARE》.2006,第29卷(第11期), * |
Graham等.Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects.《The new England journal of medicine》.2006,第354卷(第24期), * |
Lewis等.An ELISA for plasma retinol-binding protein using monoclonal and polyclonal antibodies: Plasma variation in normal and insulin resistant subjects.《Clinical Biochemistry》.2007,第40卷(第11期), * |
Takebayashi等.Retinol binding protein-4 levels and clinical features of type 2 diabetes patients.《Journal of Clinical endocrinology and metabolism》.2007,第92卷(第7期), * |
Also Published As
Publication number | Publication date |
---|---|
CN101294956A (zh) | 2008-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dieplinger et al. | Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma—The Presage™ ST2 assay | |
KR102384115B1 (ko) | 알쯔하이머병 및 다른 신경퇴행성 장애에 대한 바이오마커 및 진단 방법 | |
CN102625915A (zh) | 糖蛋白质的测定方法、肝病的检查方法、糖蛋白质定量用试剂及肝病病情指标糖链标记糖蛋白质 | |
TWI704228B (zh) | 肝癌的檢查方法 | |
Xie et al. | Development and validation of an immunochromatographic assay for rapid multi-residues detection of cephems in milk | |
EP2458378B1 (en) | Insulin measurement method | |
JP5818916B2 (ja) | 尿路感染症の診断方法 | |
Heilmann et al. | Development and analytic validation of an immunoassay for the quantification of canine S100A12 in serum and fecal samples and its biological variability in serum from healthy dogs | |
CN101294956B (zh) | 人视黄醇结合蛋白-4在代谢异常的检测中的应用 | |
Xie et al. | A high-affinity anti-salbutamol monoclonal antibody: key to a robust lateral-flow immunochromatographic assay | |
CN104470942B (zh) | 生物标志物 | |
JP2003160599A (ja) | カルボキシメチル化ペプチドに対する抗体 | |
CN108351359A (zh) | 用于预测肝硬化患者的肝细胞癌发生风险和预后的方法 | |
Le Berre et al. | Generation of a panel of high affinity antibodies and development of a biosensor-based immunoassay for the detection of okadaic acid in shellfish | |
EP2863224A1 (en) | Kit for diagnosing malignant melanoma | |
EA034364B1 (ru) | Иммуноанализ для обнаружения хромогранина а | |
CN106645750B (zh) | 一种人源性asprosin蛋白的ELISA检测试剂盒及其用途 | |
CN109402063B (zh) | 抗猪血红蛋白杂交瘤细胞株及其单克隆抗体与应用 | |
KR20100127210A (ko) | 비특이적 질환용 일반 마커로서의 ykl-40 | |
Worasith et al. | Accuracy of a new rapid diagnostic test for urinary antigen detection and assessment of drug treatment in opisthorchiasis | |
US8039226B2 (en) | Anti NC1 monoclonal antibody | |
KR102016188B1 (ko) | 교정제 및 교정 방법 | |
KR101544085B1 (ko) | 공복 혈당 장애 진단용 마커로서 gdf15 및 이를 포함하는 공복 혈당 장애 진단키트 | |
CN109997043B (zh) | 护理点测定法 | |
JP5182684B2 (ja) | カルボキシエチルアルギニンに対する抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161028 Address after: 200231 Shanghai city Xuhui District Yindu Road No. 2 Building 2 layer Patentee after: Shanghai Fang En Medical Products Co., Ltd. Address before: 200031 No. 320, Yueyang Road, Shanghai Patentee before: Shanghai Institute of life Sciences, Chinese Academy of Sciences |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 200231 Shanghai city Xuhui District Yindu Road No. 466, No. 2 Building 2 layer Patentee after: Shanghai Fang En Medical Products Co., Ltd. Address before: 200231 Shanghai city Xuhui District Yindu Road No. 2 Building 2 layer Patentee before: Shanghai Fang En Medical Products Co., Ltd. |
|
PP01 | Preservation of patent right |
Effective date of registration: 20180807 Granted publication date: 20120815 |
|
PP01 | Preservation of patent right | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20210807 Granted publication date: 20120815 |
|
PD01 | Discharge of preservation of patent | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120815 Termination date: 20180428 |
|
CF01 | Termination of patent right due to non-payment of annual fee |